2-Apr-2026
No headlines found.
Business Wire (Thu, 12-Mar 4:00 PM ET)
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Business Wire (Fri, 30-Jan 7:00 AM ET)
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
Business Wire (Wed, 7-Jan 7:00 AM ET)
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Adicet Bio trades on the NASDAQ stock market under the symbol ACET.
As of April 2, 2026, ACET stock price climbed to $6.99 with 62,256 million shares trading.
ACET has a beta of 1.62, meaning it tends to be more sensitive to market movements. ACET has a correlation of 0.15 to the broad based SPY ETF.
ACET has a market cap of $67.08 million. This is considered a Micro Cap stock.
Last quarter Adicet Bio reported $0 in Revenue and -$2.94 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.14.
In the last 3 years, ACET traded as high as $120.00 and as low as $6.01.
The top ETF exchange traded funds that ACET belongs to (by Net Assets): VTI, VXF, DFMC, DFAS.
ACET has underperformed the market in the last year with a price return of -39.7% while the SPY ETF gained +17.5%. ACET has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -20.7% and -1.1%, respectively, while the SPY returned -3.7% and -0.1%, respectively.
ACET support price is $6.58 and resistance is $7.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACET shares will trade within this expected range on the day.